Chemical: Drug
propafenone

last updated 02/07/2014

1. DPWG Guideline for propafenone and CYP2D6

Summary

Reduce the dose of propafenone by 70% for CYP2D6 poor metabolizers, and adjust propafenone dose according to plasma concentrations or use an alternative drug for CYP2D6 intermediate and ultrarapid metabolizers.

Annotation

The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for propafenone based on CYP2D6 genotype [Article:21412232]. They suggest a reduced dose for poor metabolizers, and adjusting dose according to plasma concentrations or using an alternative drug for intermediate and ultrarapid metabolizers.

Phenotype (Genotype)Therapeutic Dose RecommendationLevel of EvidenceClinical Relevance
PM (2 inactive alleles)Reduce dose by 70%, record ECG, monitor plasma concentrationPublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.Clinical effect (S): long-standing discomfort (48-168 hr) without permanent injury e.g. failure of therapy with tricyclic antidepressants, atypical antipsychotic drugs; extrapyramidal side effects; parkinsonism; ADE resulting from increased bioavailability of tricyclic antidepressants, metoprolol, propafenone (central effects e.g. dizziness); INR 4.5-6.0; neutropenia 1.0-1.5x10 9/l; leucopenia 2.0-3.0x10 9/l; thrombocytopenia 50-75x10 9/l
IM (2 decreased activity alleles, or 1 active and 1 inactive allele, or 1 decreased activity and 1 inactive allele)Insufficient data to allow calculation of dose adjustment. Adjust dose in response to plasma concentration and record ECG or select alternative drug (e.g., sotalol, disopyramide, quinidine, amiodarone)Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.Minor clinical effect (S): QTc prolongation (<450 ms male, <470 ms female); INR increase < 4.5, Kinetic effect (S)
UM (gene duplication in absence of inactive or decreased activity alleles)Insufficient data to allow calculation of dose adjustment. Adjust dose in response to plasma concentration and record ECG or select alternative drug (e.g., sotalol, disopyramide, quinidine, amiodarone)Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.Clinical effect (S): long-standing discomfort (> 168 hr), permanent symptom or invalidating injury e.g. failure of prophylaxis of atrial fibrillation; venous thromboembolism; decreased effect of clopidogrel on inhibition of platelet aggregation; ADE resulting from increased bioavailability of phenytoin; INR > 6.0; neutropenia 0.5-1.0x10 9/l; leucopenia 1.0-2.0x10 9/l; thrombocytopenia 25-50x10 9/l; severe diarrhea
Allele TypeAlleles
active*1, *2, *33, *35
decreased activity*9, *10, *17, *29, *36, *41
inactive*3-*8, *11-*16, *19-*21, *38, *40, *42
  • *See Methods or [Article:18253145] for definition of "good" and "moderate" quality.
  • S: statistically significant difference.


Annotated Labels

  1. FDA Label for propafenone and CYP2D6
  2. HCSC Label for propafenone and CYP2D6

last updated 10/25/2013

1. FDA Label for propafenone and CYP2D6

Actionable PGx

Summary

Propafenone is metabolized by CYP2D6,CYP3A4,and CYP1A2 isoenzymes. Inhibitors of CYP2D6, 1A2, and 3A4 may increase propafenone levels which may lead to cardiac arrhythmias. Simultaneous use with both a CYP3A4 and CYP2D6 inhibitor (or in a patient with CYP2D6 deficiency) should be avoided.

Annotation

Propafenone is used to treat cardiac arrhythmia, but should be used only if the condition is thought to be life-threatening.
Its metabolism is by CYP2D6,CYP3A4 and CYP1A2. The combination of propafenone, CYP3A4 inhibition and CYP2D6 inhibition or CYP2D6 genetic deficiency could be hazardous.

Excerpts from the propafenone drug label:

Propafenone is metabolized by CYP2D6,CYP3A4,and CYP1A2 isoenzymes. Approximately 6% of Caucasians in the U.S. population are naturally deficient in CYP2D6 activity and to a somewhat lesser extent in other demographic groups. Drugs that inhibit these CYP pathways(such as desipramine,paroxetine,ritonavir,sertraline for CYP2D6; ketoconazole, erythromycin, saquinavir, and grapefruit juice for CYP3A4; and amiodarone and tobacco smoke for CYP1A2) can be expected to cause increased plasma levels of propafenone.
Increased exposure to propafenone may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity. Because of its metabolism, the combination of CYP3A4 inhibition and either CYP2D6 deficiency or CYP2D6 inhibition in users of propafenone is potentially hazardous. Therefore, avoid simultaneous use of propafenone ER capsules with both a CYP2D6 inhibitor and a CYP3A4 inhibitor.

There are two genetically determined patterns of propafenone metabolism. In over 90% of patients, the drug is rapidly and extensively metabolized with an elimination half-life from 2-10 hours. These patients metabolize propafenone into two active metabolites: 5-hydroxypropafenone which is formed by CYP2D6 and N-depropylpropafenone (norpropafenone) which is formed by both CYP3A4 and CYP1A2. In less than 10% of patients, metabolism of propafenone is slower because the 5-hydroxy metabolite is not formed or is minimally formed.

For the complete drug label text with sections containing pharmacogenetic information highlighted, see the Propafenone drug label.

*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.

Full label available at DailyMed

Genes and/or phenotypes found in this label

  • Atrial Fibrillation
    • Indications & usage section
    • source: U.S. Food and Drug Administration
  • CYP1A2
    • metabolism/PK, Clinical pharmacology section
    • source: U.S. Food and Drug Administration
  • CYP2D6
    • metabolism/PK, Drug interactions section, Clinical pharmacology section
    • source: U.S. Food and Drug Administration
  • CYP3A4
    • metabolism/PK, Drug interactions section, Clinical pharmacology section
    • source: U.S. Food and Drug Administration

last updated 06/08/2015

2. HCSC Label for propafenone and CYP2D6

Actionable PGx

Summary

The product monograph for propafenone notes that individuals with reduced CYP2D6 activity may have higher plasma concentrations of the drug as compared to those who do not have reduced CYP2D6 activity.

Annotation

Propafenone is indicated for the treatment of life-threatening ventricular arrhythmias. Excerpt from the propafenone product monograph:

Due to a genetically determined presence or deficiency of one metabolizing pathway (CYP2D6), patients may be categorized into fast (over 90% of all patients) or slow metabolizers of propafenone hydrochloride, resulting in low or high plasma concentrations respectively...Slow metabolizers had higher propafenone plasma concentrations which they required for suppression of arrhythmia since they did not produce the active metabolite 5-hydroxypropafenone (5-OHP). These higher propafenone plasma concentrations may lead to clinically evident beta-blockade. Despite these differences in pharmacokinetics, steady-state conditions are achieved after three to four days of dosing in all patients...

For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the propafenone product monograph.

*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.


PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all variant annotations for propafenone

Gene ? Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
VIP CA VA CYP2D6 *1 N/A N/A N/A
VIP No VIP available No VIP available CYP2D6 *2 N/A N/A N/A
VIP No VIP available No VIP available CYP2D6 *3 N/A N/A N/A
VIP No VIP available No VIP available CYP2D6 *4 N/A N/A N/A
VIP No VIP available No VIP available CYP2D6 *6 N/A N/A N/A
VIP No VIP available No VIP available CYP2D6 *9 N/A N/A N/A
VIP CA VA CYP2D6 *10 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *10B N/A N/A N/A
VIP No VIP available No VIP available CYP2D6 *17 N/A N/A N/A
VIP No VIP available No VIP available CYP2D6 *29 N/A N/A N/A
VIP No VIP available No VIP available CYP2D6 *41 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *59 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *62 N/A N/A N/A
VIP No Clinical Annotations available No Variant Annotations available
rs1065852 NC_000022.10:g.42526694G=, NC_000022.10:g.42526694G>A, NC_000022.11:g.42130692G=, NC_000022.11:g.42130692G>A, NG_008376.3:g.4300C=, NG_008376.3:g.4300C>T, NM_000106.5:c.100C=, NM_000106.5:c.100C>T, NM_001025161.2:c.100C=, NM_001025161.2:c.100C>T, NP_000097.3:p.Pro34=, NP_000097.3:p.Pro34Ser, NP_001020332.2:p.Pro34=, NP_001020332.2:p.Pro34Ser, NT_187682.1:g.53033G=, NT_187682.1:g.53033G>A, NW_004504305.1:g.53019A=, NW_004504305.1:g.53019A>G, NW_009646208.1:g.16258A=, NW_009646208.1:g.16258A>G, XM_005278353.1:c.100T=, XM_005278353.1:c.100T>C, XM_005278354.1:c.-1454C>T, XM_005278354.1:c.-1454T>C, XM_005278354.3:c.-1454C>T, XM_005278354.3:c.-1454T>C, XM_011529966.1:c.100C=, XM_011529966.1:c.100C>T, XM_011529967.1:c.100C=, XM_011529967.1:c.100C>T, XM_011529968.1:c.100C=, XM_011529968.1:c.100C>T, XM_011529969.1:c.37+605C>T, XM_011529969.1:c.37+605T>C, XM_011529970.1:c.100C=, XM_011529970.1:c.100C>T, XM_011529971.1:c.37+605C>T, XM_011529971.1:c.37+605T>C, XM_011529972.1:c.100C=, XM_011529972.1:c.100C>T, XM_011547541.1:c.-1454C>T, XM_011547541.1:c.-1454T>C, XM_011547750.1:c.37+605C>T, XM_011547750.1:c.37+605T>C, XM_011547751.1:c.-1114C>T, XM_011547751.1:c.-1114T>C, XM_011547756.1:c.42+469A>G, XM_011547756.1:c.42+469G>A, XM_011548819.1:c.-1454C>T, XM_011548819.1:c.-1454T>C, XP_005278410.1:p.Ser34=, XP_005278410.1:p.Ser34Pro, XP_011528268.1:p.Pro34=, XP_011528268.1:p.Pro34Ser, XP_011528269.1:p.Pro34=, XP_011528269.1:p.Pro34Ser, XP_011528270.1:p.Pro34=, XP_011528270.1:p.Pro34Ser, XP_011528272.1:p.Pro34=, XP_011528272.1:p.Pro34Ser, XP_011528274.1:p.Pro34=, XP_011528274.1:p.Pro34Ser, XR_430455.2:n.328+4A>G, XR_430455.2:n.328+4G>A, XR_952536.1:n.-1751A>G, XR_952536.1:n.-1751G>A, XR_952537.1:n.-1751A>G, XR_952537.1:n.-1751G>A, XR_952538.1:n.-1751A>G, XR_952538.1:n.-1751G>A, XR_952539.1:n.-1462A>G, XR_952539.1:n.-1462G>A, XR_952745.1:n.1257C=, XR_952745.1:n.1257C>T, rs117813846, rs58862176
G > A
SNP
P34S
VIP No Clinical Annotations available No Variant Annotations available
rs16947 NC_000022.10:g.42523943A=, NC_000022.10:g.42523943A>G, NC_000022.11:g.42127941G=, NC_000022.11:g.42127941G>A, NG_008376.3:g.7051C=, NG_008376.3:g.7051C>T, NM_000106.5:c.886C=, NM_000106.5:c.886C>T, NM_001025161.2:c.733C=, NM_001025161.2:c.733C>T, NP_000097.3:p.Arg296=, NP_000097.3:p.Arg296Cys, NP_001020332.2:p.Arg245=, NP_001020332.2:p.Arg245Cys, NT_187682.1:g.50282A=, NT_187682.1:g.50282A>G, NW_004504305.1:g.50268G=, NW_004504305.1:g.50268G>A, NW_009646208.1:g.13507G=, NW_009646208.1:g.13507G>A, XM_005278353.1:c.742C=, XM_005278353.1:c.742C>T, XM_005278354.1:c.586C=, XM_005278354.1:c.586C>T, XM_005278354.3:c.586C=, XM_005278354.3:c.586C>T, XM_011529966.1:c.886C=, XM_011529966.1:c.886C>T, XM_011529967.1:c.886C=, XM_011529967.1:c.886C>T, XM_011529968.1:c.886C=, XM_011529968.1:c.886C>T, XM_011529969.1:c.742C=, XM_011529969.1:c.742C>T, XM_011529970.1:c.733C=, XM_011529970.1:c.733C>T, XM_011529971.1:c.742C=, XM_011529971.1:c.742C>T, XM_011529972.1:c.843+233C>T, XM_011529972.1:c.843+233T>C, XM_011547541.1:c.586C=, XM_011547541.1:c.586C>T, XM_011547750.1:c.742T=, XM_011547750.1:c.742T>C, XM_011547751.1:c.670T=, XM_011547751.1:c.670T>C, XM_011547756.1:c.-2094A>G, XM_011547756.1:c.-2094G>A, XM_011548819.1:c.586C=, XM_011548819.1:c.586C>T, XP_005278410.1:p.Arg248=, XP_005278410.1:p.Arg248Cys, XP_005278411.1:p.Arg196=, XP_005278411.1:p.Arg196Cys, XP_011528268.1:p.Arg296=, XP_011528268.1:p.Arg296Cys, XP_011528269.1:p.Arg296=, XP_011528269.1:p.Arg296Cys, XP_011528270.1:p.Arg296=, XP_011528270.1:p.Arg296Cys, XP_011528271.1:p.Arg248=, XP_011528271.1:p.Arg248Cys, XP_011528272.1:p.Arg245=, XP_011528272.1:p.Arg245Cys, XP_011528273.1:p.Arg248=, XP_011528273.1:p.Arg248Cys, XP_011545843.1:p.Arg196=, XP_011545843.1:p.Arg196Cys, XP_011546052.1:p.Cys248=, XP_011546052.1:p.Cys248Arg, XP_011546053.1:p.Cys224=, XP_011546053.1:p.Cys224Arg, XP_011547121.1:p.Arg196=, XP_011547121.1:p.Arg196Cys, XR_430455.2:n.-1930A>G, XR_430455.2:n.-1930G>A, XR_952745.1:n.2000+233C>T, XR_952745.1:n.2000+233T>C, rs117039205, rs57836231
A > G
SNP
R296C
VIP No Clinical Annotations available No Variant Annotations available
rs28371706 NC_000022.10:g.42525772G>A, NC_000022.11:g.42129770G>A, NG_008376.3:g.5222C>T, NM_000106.5:c.320C>T, NM_001025161.2:c.320C>T, NP_000097.3:p.Thr107Ile, NP_001020332.2:p.Thr107Ile, NT_187682.1:g.52111G>A, NW_004504305.1:g.52097G>A, NW_009646208.1:g.15336G>A, XM_005278353.1:c.320C>T, XM_005278354.1:c.-532C>T, XM_005278354.3:c.-532C>T, XM_011529966.1:c.320C>T, XM_011529967.1:c.320C>T, XM_011529968.1:c.320C>T, XM_011529969.1:c.177C>T, XM_011529970.1:c.320C>T, XM_011529971.1:c.177C>T, XM_011529972.1:c.320C>T, XM_011547541.1:c.-532C>T, XM_011547750.1:c.177C>T, XM_011547751.1:c.-192C>T, XM_011547756.1:c.-265G>A, XM_011548819.1:c.-532C>T, XP_005278410.1:p.Thr107Ile, XP_011528268.1:p.Thr107Ile, XP_011528269.1:p.Thr107Ile, XP_011528270.1:p.Thr107Ile, XP_011528271.1:p.His59=, XP_011528272.1:p.Thr107Ile, XP_011528273.1:p.His59=, XP_011528274.1:p.Thr107Ile, XP_011546052.1:p.His59=, XR_430455.2:n.-101G>A, XR_952745.1:n.1477C>T, rs587777915, rs59604033
G > A
SNP
T107I
VIP No Clinical Annotations available No Variant Annotations available
rs28371725 NC_000022.10:g.42523805C>T, NC_000022.11:g.42127803C>T, NG_008376.3:g.7189G>A, NM_000106.5:c.985+39G>A, NM_001025161.2:c.832+39G>A, NT_187682.1:g.50144C>T, NW_004504305.1:g.50130C>T, NW_009646208.1:g.13369C>T, XM_005278353.1:c.841+39G>A, XM_005278354.1:c.685+39G>A, XM_005278354.3:c.685+39G>A, XM_011529966.1:c.985+39G>A, XM_011529967.1:c.985+39G>A, XM_011529968.1:c.985+39G>A, XM_011529969.1:c.841+39G>A, XM_011529970.1:c.832+39G>A, XM_011529971.1:c.841+39G>A, XM_011529972.1:c.844-169G>A, XM_011547541.1:c.724G>A, XM_011547750.1:c.841+39G>A, XM_011547751.1:c.769+39G>A, XM_011548819.1:c.724G>A, XP_011545843.1:p.Glu242Lys, XP_011547121.1:p.Glu242Lys, XR_952745.1:n.2001-169G>A, rs57124011, rs587777916
C > T
SNP
VIP No Clinical Annotations available No Variant Annotations available
rs35742686 NC_000022.10:g.42524244delT, NC_000022.11:g.42128242delT, NG_008376.3:g.6750delA, NM_000106.5:c.775delA, NM_001025161.2:c.622delA, NP_000097.3:p.Arg259Glyfs, NP_001020332.2:p.Arg208Glyfs, NT_187682.1:g.50583delT, NW_004504305.1:g.50569delT, NW_009646208.1:g.13808delT, XM_005278353.1:c.631delA, XM_005278354.1:c.475delA, XM_005278354.3:c.475delA, XM_011529966.1:c.775delA, XM_011529967.1:c.775delA, XM_011529968.1:c.775delA, XM_011529969.1:c.631delA, XM_011529970.1:c.622delA, XM_011529971.1:c.631delA, XM_011529972.1:c.775delA, XM_011547541.1:c.475delA, XM_011547750.1:c.631delA, XM_011547751.1:c.559delA, XM_011547756.1:c.-1793delT, XM_011548819.1:c.475delA, XP_005278410.1:p.Arg211Glyfs, XP_005278411.1:p.Arg159Glyfs, XP_011528268.1:p.Arg259Glyfs, XP_011528269.1:p.Arg259Glyfs, XP_011528270.1:p.Arg259Glyfs, XP_011528271.1:p.Arg211Glyfs, XP_011528272.1:p.Arg208Glyfs, XP_011528273.1:p.Arg211Glyfs, XP_011528274.1:p.Arg259Glyfs, XP_011545843.1:p.Arg159Glyfs, XP_011546052.1:p.Arg211Glyfs, XP_011546053.1:p.Arg187Glyfs, XP_011547121.1:p.Arg159Glyfs, XR_430455.2:n.-1629delT, XR_952745.1:n.1932delA, rs45593132, rs60790764
T > -
T > T
indel
R259G
VIP No Clinical Annotations available No Variant Annotations available
rs3892097 NC_000022.10:g.42524947C=, NC_000022.10:g.42524947C>T, NC_000022.11:g.42128945C=, NC_000022.11:g.42128945C>T, NG_008376.3:g.6047G=, NG_008376.3:g.6047G>A, NM_000106.5:c.506-1A>G, NM_000106.5:c.506-1G>A, NM_001025161.2:c.353-1A>G, NM_001025161.2:c.353-1G>A, NT_187682.1:g.51286C=, NT_187682.1:g.51286C>T, NW_004504305.1:g.51272T=, NW_004504305.1:g.51272T>C, NW_009646208.1:g.14511C=, NW_009646208.1:g.14511C>T, XM_005278353.1:c.363-2A>G, XM_005278353.1:c.363-2G>A, XM_005278354.1:c.207-2A>G, XM_005278354.1:c.207-2G>A, XM_005278354.3:c.207-2A>G, XM_005278354.3:c.207-2G>A, XM_011529966.1:c.506-1A>G, XM_011529966.1:c.506-1G>A, XM_011529967.1:c.506-1A>G, XM_011529967.1:c.506-1G>A, XM_011529968.1:c.506-1A>G, XM_011529968.1:c.506-1G>A, XM_011529969.1:c.363-2A>G, XM_011529969.1:c.363-2G>A, XM_011529970.1:c.353-1A>G, XM_011529970.1:c.353-1G>A, XM_011529971.1:c.363-2A>G, XM_011529971.1:c.363-2G>A, XM_011529972.1:c.506-1A>G, XM_011529972.1:c.506-1G>A, XM_011547541.1:c.207-2A>G, XM_011547541.1:c.207-2G>A, XM_011547750.1:c.363-2A>G, XM_011547750.1:c.363-2G>A, XM_011547751.1:c.290-1A>G, XM_011547751.1:c.290-1G>A, XM_011547756.1:c.-1090C>T, XM_011547756.1:c.-1090T>C, XM_011548819.1:c.207-2A>G, XM_011548819.1:c.207-2G>A, XR_430455.2:n.-926C>T, XR_430455.2:n.-926T>C, XR_952745.1:n.1663-1A>G, XR_952745.1:n.1663-1G>A, rs1800716, rs28371711, rs60082401, rs606231227
C > T
SNP
VIP No Clinical Annotations available No Variant Annotations available
rs5030655 NC_000022.10:g.42525086delA, NC_000022.11:g.42129084delA, NG_008376.3:g.5908delT, NM_000106.5:c.454delT, NM_001025161.2:c.353-140delT, NP_000097.3:p.Trp152Glyfs, NT_187682.1:g.51425delA, NW_004504305.1:g.51411delA, NW_009646208.1:g.14650delA, XM_005278353.1:c.363-141delT, XM_005278354.1:c.155delT, XM_005278354.3:c.155delT, XM_011529966.1:c.454delT, XM_011529967.1:c.454delT, XM_011529968.1:c.454delT, XM_011529969.1:c.311delT, XM_011529970.1:c.353-140delT, XM_011529971.1:c.311delT, XM_011529972.1:c.454delT, XM_011547541.1:c.155delT, XM_011547750.1:c.311delT, XM_011547751.1:c.238delT, XM_011547756.1:c.-951delA, XM_011548819.1:c.155delT, XP_005278411.1:p.Val52Glyfs, XP_011528268.1:p.Trp152Glyfs, XP_011528269.1:p.Trp152Glyfs, XP_011528270.1:p.Trp152Glyfs, XP_011528271.1:p.Val104Glyfs, XP_011528273.1:p.Val104Glyfs, XP_011528274.1:p.Trp152Glyfs, XP_011545843.1:p.Val52Glyfs, XP_011546052.1:p.Val104Glyfs, XP_011546053.1:p.Trp80Glyfs, XP_011547121.1:p.Val52Glyfs, XR_430455.2:n.-787delA, XR_952745.1:n.1611delT, rs11568727, rs28371709
A > -
A > A
indel
W152G
VIP No Clinical Annotations available No Variant Annotations available
rs5030656 NC_000022.10:g.42524176_42524178delCTT, NC_000022.11:g.42128174_42128176delCTT, NG_008376.3:g.6816_6818delAAG, NM_000106.5:c.841_843delAAG, NM_001025161.2:c.688_690delAAG, NP_000097.3:p.Lys281del, NP_001020332.2:p.Lys230del, NT_187682.1:g.50515_50517delCTT, NW_004504305.1:g.50501_50503delCTT, NW_009646208.1:g.13740_13742delCTT, XM_005278353.1:c.697_699delAAG, XM_005278354.1:c.541_543delAAG, XM_005278354.3:c.541_543delAAG, XM_011529966.1:c.841_843delAAG, XM_011529967.1:c.841_843delAAG, XM_011529968.1:c.841_843delAAG, XM_011529969.1:c.697_699delAAG, XM_011529970.1:c.688_690delAAG, XM_011529971.1:c.697_699delAAG, XM_011529972.1:c.841_843delAAG, XM_011547541.1:c.541_543delAAG, XM_011547750.1:c.697_699delAAG, XM_011547751.1:c.625_627delAAG, XM_011547756.1:c.-1861_-1859del, XM_011548819.1:c.541_543delAAG, XP_005278410.1:p.Lys233del, XP_005278411.1:p.Lys181del, XP_011528268.1:p.Lys281del, XP_011528269.1:p.Lys281del, XP_011528270.1:p.Lys281del, XP_011528271.1:p.Lys233del, XP_011528272.1:p.Lys230del, XP_011528273.1:p.Lys233del, XP_011528274.1:p.Lys281del, XP_011545843.1:p.Lys181del, XP_011546052.1:p.Lys233del, XP_011546053.1:p.Lys209del, XP_011547121.1:p.Lys181del, XR_430455.2:n.-1697_-1695del, XR_952745.1:n.1998_2000delAAG, rs587777919
CTT > -
CTT > CTT
indel
VIP No Clinical Annotations available No Variant Annotations available
rs59421388 NC_000022.10:g.42523610C>T, NC_000022.11:g.42127608C>T, NG_008376.3:g.7384G>A, NM_000106.5:c.1012G>A, NM_001025161.2:c.859G>A, NP_000097.3:p.Val338Met, NP_001020332.2:p.Val287Met, NT_187682.1:g.49949C>T, NW_004504305.1:g.49935C>T, NW_009646208.1:g.13174C>T, XM_005278353.1:c.868G>A, XM_005278354.1:c.712G>A, XM_005278354.3:c.712G>A, XM_011529966.1:c.1012G>A, XM_011529967.1:c.1012G>A, XM_011529968.1:c.1012G>A, XM_011529969.1:c.868G>A, XM_011529970.1:c.859G>A, XM_011529971.1:c.868G>A, XM_011529972.1:c.870G>A, XM_011547541.1:c.*118G>A, XM_011547750.1:c.868G>A, XM_011547751.1:c.796G>A, XM_011548819.1:c.*118G>A, XP_005278410.1:p.Val290Met, XP_005278411.1:p.Val238Met, XP_011528268.1:p.Val338Met, XP_011528269.1:p.Val338Met, XP_011528270.1:p.Val338Met, XP_011528271.1:p.Val290Met, XP_011528272.1:p.Val287Met, XP_011528273.1:p.Val290Met, XP_011528274.1:p.Thr290=, XP_011546052.1:p.Val290Met, XP_011546053.1:p.Val266Met, XR_952745.1:n.2027G>A
C > T
SNP
V338M
VIP No Clinical Annotations available No Variant Annotations available
rs61736512 NC_000022.10:g.42525134C>T, NC_000022.11:g.42129132C>T, NG_008376.3:g.5860G>A, NM_000106.5:c.406G>A, NM_001025161.2:c.353-188G>A, NP_000097.3:p.Val136Met, NT_187682.1:g.51473C>T, NW_004504305.1:g.51459C>T, NW_009646208.1:g.14698C>T, XM_005278353.1:c.363-189G>A, XM_005278354.1:c.107G>A, XM_005278354.3:c.107G>A, XM_011529966.1:c.406G>A, XM_011529967.1:c.406G>A, XM_011529968.1:c.406G>A, XM_011529969.1:c.263G>A, XM_011529970.1:c.353-188G>A, XM_011529971.1:c.263G>A, XM_011529972.1:c.406G>A, XM_011547541.1:c.107G>A, XM_011547750.1:c.263G>A, XM_011547751.1:c.190G>A, XM_011547756.1:c.-903C>T, XM_011548819.1:c.107G>A, XP_005278411.1:p.Arg36His, XP_011528268.1:p.Val136Met, XP_011528269.1:p.Val136Met, XP_011528270.1:p.Val136Met, XP_011528271.1:p.Arg88His, XP_011528273.1:p.Arg88His, XP_011528274.1:p.Val136Met, XP_011545843.1:p.Arg36His, XP_011546052.1:p.Arg88His, XP_011546053.1:p.Val64Ile, XP_011547121.1:p.Arg36His, XR_430455.2:n.-739C>T, XR_952745.1:n.1563G>A
C > T
SNP
V136M
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Generic Names
  • Propafenona [INN-Spanish]
  • Propafenone HCl
  • Propafenone hydrochloride
  • Propafenone-HCl
  • Propafenonum [INN-Latin]
Trade Names
  • Rythmol
  • Rythmol SR
Brand Mixture Names

PharmGKB Accession Id

PA451131

Type(s):

Drug

Description

An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated.

Source: Drug Bank

Indication

Used to prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. Also used for the treatment of life-threatening documented ventricular arrhythmias, such as sustained ventricular tachycardia.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

The electrophysiological effect of propafenone manifests itself in a reduction of upstroke velocity (Phase 0) of the monophasic action potential. In Purkinje fibers, and to a lesser extent myocardial fibers, propafenone reduces the fast inward current carried by sodium ions, which is responsible for the drugs antiarrhythmic actions. Diastolic excitability threshold is increased and effective refractory period prolonged. Propafenone reduces spontaneous automaticity and depresses triggered activity. At very high concentrations in vitro, propafenone can inhibit the slow inward current carried by calcium but this calcium antagonist effect probably does not contribute to antiarrhythmic efficacy.

Source: Drug Bank

Pharmacology

Propafenone is a Class 1C antiarrhythmic drug with local anesthetic effects, and a direct stabilizing action on myocardial membranes. It is used in the treatment of atrial and ventricular arrhythmias. It works by slowing the influx of sodium ions into the cardiac muscle cells, causing a decrease in excitablity of the cells. Propafenone has local anesthetic activity approximately equal to procaine.

Source: Drug Bank

Food Interaction

Grapefruit and grapefruit juice should be avoided throughout treatment. Grapefruit can increase serum levels of this product.|Always take at the same time in regard to meals.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Metabolized primarily in the liver where it is rapidly and extensively metabolized to two active metabolites, 5-hydroxypropafenone and N-depropylpropafenone. These metabolites have antiarrhythmic activity comparable to propafenone but are present in concentrations less than 25% of propafenone concentrations.

Source: Drug Bank

Protein Binding

97%

Source: Drug Bank

Absorption

Nearly completely absorbed following oral administration (90%). Systemic bioavailability ranges from 5 to 50%, due to significant first-pass metabolism. This wide range in systemic bioavailability is related to two factors: presence of food (food increases bioavailability) and dosage (bioavailability is 3.4% for a 150-mg tablet compared to 10.6% for a 300-mg tablet).

Source: Drug Bank

Half-Life

2-10 hours

Source: Drug Bank

Toxicity

Symptoms of propafenone overdose (usually most severe within the first 3 hours) may include convulsions (rarely), heartbeat irregularities, low blood pressure, and sleepiness.

Source: Drug Bank

Route of Elimination

Naloxone is metabolized in the liver primarily by glucuronide conjugation with naloxone-3-glucuronide as the major metabolite. After an oral or intravenous dose, about 25 to 40% of the drug is excreted as metabolites in urine within 6 hours.

Source: Drug Bank

Volume of Distribution

  • 252 L

Source: Drug Bank

Chemical Properties

Chemical Formula

C21H27NO3

Source: Drug Bank

Isomeric SMILES

CCCNC[C@H](COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O

Source: Drug Bank

CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1

Source: Drug Bank

Canonical SMILES

CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1

Source: Drug Bank

Average Molecular Weight

341.444

Source: Drug Bank

Monoisotopic Molecular Weight

341.199093735

Source: Drug Bank

SMILES

CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1

Source: Drug Bank

InChI String

InChI=1S/C21H27NO3/c1-2-14-22-15-18(23)16-25-21-11-7-6-10-19(21)20(24)13-12-17-8-4-3-5-9-17/h3-11,18,22-23H,2,12-16H2,1H3

Source: Drug Bank

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Antiarrhythmic Pathway, Pharmacodynamics
    Pharmacodynamic pathway of antiarrhythmic drugs in a stylized cardiac myocyte.

External Pathways

Links to non-PharmGKB pathways.

PharmGKB contains no links to external pathways for this drug. To report a pathway, click here.

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

Drug Targets

Gene Description
ABCB1 (source: Drug Bank)
KCNH2 (source: Drug Bank)
SCN5A (source: Drug Bank)

Drug Interactions

Interaction Description
aminophylline - propafenone Propafenone increases the effect of theophylline (source: Drug Bank)
atomoxetine - propafenone The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine (source: Drug Bank)
cisapride - propafenone Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
cisapride - propafenone Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
cyclosporine - propafenone Propafenone increases the effect and toxicity of cyclosporine (source: Drug Bank)
cyclosporine - propafenone Propafenone increases the effect and toxicity of cyclosporine (source: Drug Bank)
digoxin - propafenone Propafenone increases the effect of digoxin (source: Drug Bank)
digoxin - propafenone Propafenone increases the effect of digoxin (source: Drug Bank)
duloxetine - propafenone Possible increase in the levels of this agent when used with duloxetine (source: Drug Bank)
duloxetine - propafenone Possible increase in the levels of this agent when used with duloxetine (source: Drug Bank)
fluoxetine - propafenone Increases the effect and toxicity of propafenone (source: Drug Bank)
fluoxetine - propafenone Increases the effect and toxicity of propafenone (source: Drug Bank)
mesoridazine - propafenone Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
mesoridazine - propafenone Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
metoprolol - propafenone Propafenone increases the effect of beta-blocker (source: Drug Bank)
metoprolol - propafenone Propafenone may increase the effect of beta-blocker, metoprolol. (source: Drug Bank)
mexiletine - propafenone Propafenone increases the effects/toxicity of mexiletine (source: Drug Bank)
mexiletine - propafenone Propafenone increases the effects/toxicity of mexiletine (source: Drug Bank)
oxtriphylline - propafenone Propafenone increases the effect of theophylline (source: Drug Bank)
propafenone - acenocoumarol The agent increases the effect of anticoagulant (source: Drug Bank)
propafenone - acenocoumarol Propafenone may increase the anticoagulant effect of acenocoumarol. (source: Drug Bank)
propafenone - aminophylline Propafenone increases the effect of theophylline (source: Drug Bank)
propafenone - aminophylline Propafenone increases the effect of theophylline (source: Drug Bank)
propafenone - anisindione The agent increases the effect of anticoagulant (source: Drug Bank)
propafenone - anisindione Propafenone may increase the anticoagulant effect of anisindione. (source: Drug Bank)
propafenone - atomoxetine Tje CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine (source: Drug Bank)
propafenone - atomoxetine Tje CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine (source: Drug Bank)
propafenone - cisapride Increased risk of cardiotoxicity and arrhytmias (source: Drug Bank)
propafenone - cisapride Increased risk of cardiotoxicity and arrhytmias (source: Drug Bank)
propafenone - cyclosporine Propafenone increases the effect and toxicity of cyclosporine (source: Drug Bank)
propafenone - cyclosporine Propafenone increases the effect and toxicity of cyclosporine (source: Drug Bank)
propafenone - dicumarol The agent increases the effect of anticoagulant (source: Drug Bank)
propafenone - dicumarol Propafenone may increase the anticoagulant effect of dicumarol. (source: Drug Bank)
propafenone - digoxin Propafenone increases the effect of digoxin (source: Drug Bank)
propafenone - digoxin Propafenone increases the effect of digoxin (source: Drug Bank)
propafenone - duloxetine Possible increase in the levels of this agent when used with duloxetine (source: Drug Bank)
propafenone - duloxetine Possible increase in the levels of this agent when used with duloxetine (source: Drug Bank)
propafenone - dyphylline Propafenone increases the effect of theophylline (source: Drug Bank)
propafenone - dyphylline Propafenone increases the effect of theophylline (source: Drug Bank)
propafenone - fluoxetine Fluoxetine increases the effect and toxicity of propafenone (source: Drug Bank)
propafenone - fluoxetine Fluoxetine increases the effect and toxicity of propafenone (source: Drug Bank)
propafenone - mesoridazine Increased risk of cardiotoxicity and arrhytmias (source: Drug Bank)
propafenone - mesoridazine Increased risk of cardiotoxicity and arrhytmias (source: Drug Bank)
propafenone - metoprolol Propafenone increases the effect of the beta-blocker (source: Drug Bank)
propafenone - metoprolol Propafenone increases the effect of the beta-blocker (source: Drug Bank)
propafenone - mexiletine Propafenone increases the effect and toxicity of mexilitine (source: Drug Bank)
propafenone - mexiletine Propafenone increases the effect and toxicity of mexilitine (source: Drug Bank)
propafenone - oxtriphylline Propafenone increases the effect of theophylline (source: Drug Bank)
propafenone - oxtriphylline Propafenone increases the effect of theophylline (source: Drug Bank)
propafenone - paroxetine Fluoxetine increases the effect and toxicity of propafenone (source: Drug Bank)
propafenone - paroxetine Fluoxetine increases the effect and toxicity of propafenone (source: Drug Bank)
propafenone - propranolol Propafenone increases the effect of the beta-blocker (source: Drug Bank)
propafenone - propranolol Propafenone increases the effect of the beta-blocker (source: Drug Bank)
propafenone - quinidine Quinidine increases the effect of propafenone (source: Drug Bank)
propafenone - quinidine Quinidine increases the effect of propafenone (source: Drug Bank)
propafenone - quinidine Quinidine increases the effect of propafenone (source: Drug Bank)
propafenone - rifabutin Rifampin decreases the effect of propafenone (source: Drug Bank)
propafenone - rifabutin Rifampin decreases the effect of propafenone (source: Drug Bank)
propafenone - rifampin Rifampin decreases the effect of propafenone (source: Drug Bank)
propafenone - rifampin Rifampin decreases the effect of propafenone (source: Drug Bank)
propafenone - ritonavir Ritonavir increases the effect and toxicity of propafenone (source: Drug Bank)
propafenone - ritonavir Ritonavir increases the effect and toxicity of propafenone (source: Drug Bank)
propafenone - sertraline Fluoxetine increases the effect and toxicity of propafenone (source: Drug Bank)
propafenone - sertraline Fluoxetine increases the effect and toxicity of propafenone (source: Drug Bank)
propafenone - terfenadine Increased risk of cardiotoxicity and arrhytmias (source: Drug Bank)
propafenone - terfenadine Increased risk of cardiotoxicity and arrhytmias (source: Drug Bank)
propafenone - theophylline Propafenone increases the effect of theophylline (source: Drug Bank)
propafenone - theophylline Propafenone increases the effect of theophylline (source: Drug Bank)
propafenone - thioridazine Increased risk of cardiotoxicity and arrhytmias (source: Drug Bank)
propafenone - thioridazine Increased risk of cardiotoxicity and arrhytmias (source: Drug Bank)
propafenone - venlafaxine Propafenone increases the effect and toxicity of venlafaxine (source: Drug Bank)
propafenone - venlafaxine Propafenone increases the effect and toxicity of venlafaxine (source: Drug Bank)
propafenone - warfarin The agent increases the effect of anticoagulant (source: Drug Bank)
propafenone - warfarin Propafenone may increase the anticoagulant effect of warfarin. (source: Drug Bank)
propranolol - propafenone Propafenone increases the effect of the beta-blocker (source: Drug Bank)
propranolol - propafenone Propafenone may increase the effect of the beta-blocker, propranolol. (source: Drug Bank)
quinidine - propafenone Quinidine increases the effect of propafenone (source: Drug Bank)
quinidine - propafenone Quinidine increases the effect of propafenone (source: Drug Bank)
rifabutin - propafenone Rifampin decreases the effect of propafenone (source: Drug Bank)
rifabutin - propafenone Rifampin decreases the effect of propafenone (source: Drug Bank)
rifampin - propafenone Rifampin decreases the effect of propafenone (source: Drug Bank)
rifampin - propafenone Rifampin decreases the effect of propafenone (source: Drug Bank)
terfenadine - propafenone Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
terfenadine - propafenone Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
theophylline - propafenone Propafenone increases the effect of theophylline (source: Drug Bank)
theophylline - propafenone Propafenone increases the effect of theophylline (source: Drug Bank)
thiopental - propafenone Thiopental may increase the metabolism and clearance of Propafenone. Monitor for decreased therapeutic effect of Propafenone if Thiopental is initiated. (source: Drug Bank)
thiopental - propafenone Thiopental may increase the metabolism and clearance of Propafenone. Monitor for decreased therapeutic effect of Propafenone if Thiopental is initiated. (source: Drug Bank)
thioridazine - propafenone Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - propafenone Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thiothixene - propafenone May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. (source: Drug Bank)
thiothixene - propafenone May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. (source: Drug Bank)
tipranavir - propafenone Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Propafenone. Concomitant therapy is contraindicated. (source: Drug Bank)
tizanidine - propafenone Propafenone may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration. (source: Drug Bank)
toremifene - propafenone Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration. (source: Drug Bank)
trazodone - propafenone The 2D6 inhibitor, Trazodone, may increase the efficacy of Propafenone by decreasing Propafenone metabolism and clearance. Monitor for changes in Propafenone efficacy if Trazodone is initiated, discontinued or dose changed. (source: Drug Bank)
trazodone - propafenone The 2D6 inhibitor, Trazodone, may increase the efficacy of Propafenone by decreasing Propafenone metabolism and clearance. Monitor for changes in Propafenone efficacy if Trazodone is initiated, discontinued or dose changed. (source: Drug Bank)
trimipramine - propafenone Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. (source: Drug Bank)
voriconazole - propafenone Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank)
vorinostat - propafenone Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank)
ziprasidone - propafenone Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated. (source: Drug Bank)
zuclopenthixol - propafenone Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank)

Curated Information ?

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
Contraindicated With

Publications related to propafenone: 14

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Challenges in pharmacogenetics. European journal of clinical pharmacology. 2013. Cascorbi Ingolf, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics: the genetics of variable drug responses. Circulation. 2011. Roden Dan M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics: From Bench to Byte- An Update of Guidelines. Clinical pharmacology and therapeutics. 2011. Swen J J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenetics and genomics. 2011. Hodges Laura M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Modulation of drug block of the cardiac potassium channel KCNA5 by the drug transporters OCTN1 and MDR1. British journal of pharmacology. 2010. Yang Tao, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Systematic review of pharmacoeconomic studies of pharmacogenomic tests. Pharmacogenomics. 2010. Beaulieu Mathieu, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Warfarin interactions with substances listed in drug information compendia and in the FDA-approved label for warfarin sodium. Clinical pharmacology and therapeutics. 2009. Anthony M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Cytochrome P450 2D6. Pharmacogenetics and genomics. 2009. Owen Ryan P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica; the fate of foreign compounds in biological systems. 2008. Zhou S-F. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
A natural variant of the heme-binding signature (R441C) resulting in complete loss of function of CYP2D6. Drug metabolism and disposition: the biological fate of chemicals. 2007. Klein Kathrin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
A silent mutation (2939G>A, exon 6; CYP2D6*59) leading to impaired expression and function of CYP2D6. Pharmacogenetics and genomics. 2006. Toscano Claudia, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of CYP2D6*10B genotype on pharmacokinetics of propafenone enantiomers in Chinese subjects. Acta pharmacologica Sinica. 2003. Chen Bing, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effect of CYP2D6*10 genotype on propafenone pharmacodynamics in Chinese patients with ventricular arrhythmia. Acta pharmacologica Sinica. 2002. Cai Wei-Min, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone. The New England journal of medicine. 1990. Lee J T, et al. PubMed

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
0173-0786-01
DrugBank:
DB01182
KEGG Compound:
C07381
PubChem Compound:
4932
PubChem Substance:
181774
46504529
IUPHAR Ligand:
2561
Drugs Product Database (DPD):
2243728
BindingDB:
50067133
ChemSpider:
4763
Therapeutic Targets Database:
DAP000497
FDA Drug Label at DailyMed:
0e9d1433-a55e-4907-bb38-abac47c7d3c7

Clinical Trials

These are trials that mention propafenone and are related to either pharmacogenetics or pharmacogenomics.

No trials loaded.

NURSA Datasets

provided by nursa.org

No NURSA datasets available.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.